688131 皓元医药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)5.1447.4845.2789.35016.253
总资产报酬率 ROA (%)2.6754.1583.2726.47411.784
投入资产回报率 ROIC (%)2.9764.7083.7857.55513.863

边际利润分析
销售毛利率 (%)49.06947.96545.16851.44454.118
营业利润率 (%)14.09110.4326.82614.47421.641
息税前利润/营业总收入 (%)15.12712.0208.51314.57722.261
净利润/营业总收入 (%)11.3438.7196.71814.10519.662

收益指标分析
经营活动净收益/利润总额(%)125.089154.935161.741107.449109.025
价值变动净收益/利润总额(%)0.804-5.709-3.7238.085-0.057
营业外收支净额/利润总额(%)-1.7080.645-0.1060.995-0.111

偿债能力分析
流动比率 (X)2.4262.5191.8802.2174.944
速动比率 (X)1.5211.5970.8961.1093.849
资产负债率 (%)47.85847.24339.73935.18322.986
带息债务/全部投入资本 (%)35.85633.21224.23215.3670.695
股东权益/带息债务 (%)158.885177.147282.011492.78912,717.344
股东权益/负债合计 (%)108.118110.658150.611183.280332.471
利息保障倍数 (X)11.8837.9065.025-342.76634.569

营运能力分析
应收账款周转天数 (天)77.74077.06175.32063.74341.668
存货周转天数 (天)333.213351.690359.057344.748235.069